Plant ID: NPO7635
Plant Latin Name: Glycine max
Taxonomy Genus: Glycine
Taxonomy Family: Fabaceae
NCBI TaxonomyDB:
3847
Plant-of-the-World-Online:
60450240-2
Antidote; Astringent; Diaphoretic; Laxative; Ophthalmic; Resolvent; Stomachic
Brazil; Canada; Bangladesh; Guinea; Nepal; Cambodia; Ethiopia; Tanzania; Laos; Cameroon; Ecuador; Benin; Belarus; Cuba; China; Vietnam; Thailand; Dominican Republic; Iraq; Kazakhstan; Taiwan; Ukraine; Philippines; Indonesia; Turkmenistan; New Caledonia; United States; Trinidad and Tobago; Australia; Mongolia; Kenya; Russia; Pakistan; Honduras; Myanmar; Chad; South Africa; India; Uzbekistan; Congo; Colombia; Sri Lanka; Japan; South Korea; Tajikistan
TSHR; | |
BLM; TDP1; HSD17B1; AKR1B1; GFER; AOX1; | |
ACHE; | |
EGFR; KDR; AURKB; AURKA; CSNK2A1; | |
CA12; CA9; CA5B; CA5A; CA3; CA14; CA7; CA4; CA6; | |
ESR2; ESR1; | |
ESRRB; ESRRA; | |
ALDH2; | |
F2; | |
LMNA; THPO; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
Enzyme_unclassified | AOX1 | Aldehyde oxidase | Q06278 | CHEMBL3257 |
Enzyme_unclassified | BLM | Bloom syndrome protein | P54132 | CHEMBL1293237 |
Enzyme_unclassified | TDP1 | Tyrosyl-DNA phosphodiesterase 1 | Q9NUW8 | CHEMBL1075138 |
Enzyme_unclassified | HSD17B1 | Estradiol 17-beta-dehydrogenase 1 | P14061 | CHEMBL3181 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Enzyme_unclassified | GFER | FAD-linked sulfhydryl oxidase ALR | P55789 | CHEMBL1741189 |
Hydrolase | ACHE | Acetylcholinesterase | P22303 | CHEMBL220 |
Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
Lyase | CA5B | Carbonic anhydrase VB | Q9Y2D0 | CHEMBL3969 |
Lyase | CA5A | Carbonic anhydrase VA | P35218 | CHEMBL4789 |
Lyase | CA3 | Carbonic anhydrase III | P07451 | CHEMBL2885 |
Lyase | CA14 | Carbonic anhydrase XIV | Q9ULX7 | CHEMBL3510 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Lyase | CA6 | Carbonic anhydrase VI | P23280 | CHEMBL3025 |
Nuclear hormone receptor subfamily 3 group A | ESR2 | Estrogen receptor beta | Q92731 | CHEMBL242 |
Nuclear hormone receptor subfamily 3 group A | ESR1 | Estrogen receptor alpha | P03372 | CHEMBL206 |
Nuclear hormone receptor subfamily 3 group B | ESRRB | Estrogen-related receptor beta | O95718 | CHEMBL3751 |
Nuclear hormone receptor subfamily 3 group B | ESRRA | Estrogen-related receptor alpha | P11474 | CHEMBL3429 |
Oxidoreductase | ALDH2 | Aldehyde dehydrogenase | P05091 | CHEMBL1935 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Protein Kinase | EGFR | Epidermal growth factor receptor erbB1 | P00533 | CHEMBL203 |
Protein Kinase | KDR | Vascular endothelial growth factor receptor 2 | P35968 | CHEMBL279 |
Protein Kinase | AURKB | Serine/threonine-protein kinase Aurora-B | Q96GD4 | CHEMBL2185 |
Protein Kinase | AURKA | Serine/threonine-protein kinase Aurora-A | O14965 | CHEMBL4722 |
Protein Kinase | CSNK2A1 | Casein kinase II alpha | P68400 | CHEMBL3629 |
Serine protease | F2 | Thrombin | P00734 | CHEMBL204 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0008270; zinc ion binding | 7.396E-10 | 1.789E-06 | BLM, CA12, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9, ESR1, ESR2, ESRRA, ESRRB |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.882E-09 | 4.097E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 1.681E-08 | 2.615E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 5.288E-08 | 6.060E-05 | CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 7.803E-08 | 8.496E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.913E-07 | 3.277E-04 | AOX1, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
MF | GO:0005488; binding | GO:0005496; steroid binding | 4.545E-07 | 3.535E-04 | ESR1, ESR2, ESRRA, ESRRB, HSD17B1 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 1.414E-06 | 9.329E-04 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2 |
MF | GO:0060089; molecular transducer activity | GO:0038052; RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA binding | 3.190E-06 | 1.615E-03 | ESR1, ESR2 |
MF | GO:0005488; binding | GO:0020037; heme binding | 3.270E-06 | 1.618E-03 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 9.415E-06 | 4.020E-03 | CYP1A1, CYP1A2, CYP1B1 |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.033E-05 | 4.326E-03 | AKR1B1, ALDH2, AOX1, CYP19A1, CYP1A2 |
BP | GO:0050896; response to stimulus | GO:0009611; response to wounding | 1.674E-05 | 6.397E-03 | ACHE, AURKA, CYP1A1, EGFR, F2 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 1.909E-05 | 6.706E-03 | CYP1A1, CYP1A2 |
MF | GO:0005488; binding | GO:0034056; estrogen response element binding | 1.909E-05 | 6.706E-03 | ESR1, ESR2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.909E-05 | 6.706E-03 | CYP1A2, CYP2C9 |
BP | GO:0008152; metabolic process | GO:0046777; protein autophosphorylation | 2.591E-05 | 8.548E-03 | AURKA, AURKB, CSNK2A1, EGFR, KDR |
BP | GO:0023052; signaling | GO:0023051; regulation of signaling | 2.818E-05 | 9.025E-03 | ACHE, AKR1B1, AURKA, AURKB, BLM, CA7, CSNK2A1, CYP19A1, CYP1B1, EGFR, ESR1, ESR2, F2, GFER, KDR, LMNA, THPO |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.138E-05 | 9.354E-03 | CYP19A1, CYP1A1, CYP2C9 |
CC | GO:0032991; macromolecular complex | GO:0032133; chromosome passenger complex | 3.179E-05 | 9.354E-03 | AURKA, AURKB |
MF | GO:0003824; catalytic activity | GO:0004089; carbonate dehydratase activity | 3.407E-22 | 7.419E-18 | CA12, CA14, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0051179; localization | GO:0015701; bicarbonate transport | 4.659E-17 | 5.073E-13 | CA12, CA14, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
BP | GO:0008152; metabolic process | GO:0006730; one-carbon metabolic process | 1.433E-15 | 7.802E-12 | CA12, CA3, CA4, CA5A, CA5B, CA6, CA7, CA9 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.207E-21 | 1.111E-19 | CA12, CA3, CA5B, CA5A, CA4, CA7, CA6, CA9, CA14 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 7.671E-09 | 3.529E-07 | ALDH2, CYP1A2, CYP1A1, AOX1, CYP1B1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 5.223E-08 | 1.602E-06 | HSD17B1, CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.709E-06 | 3.931E-05 | HSD17B1, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 4.931E-06 | 9.074E-05 | CYP2C9, CYP1A2, CYP1A1, AOX1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 7.850E-06 | 1.204E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 1.247E-05 | 1.639E-04 | CYP2C9, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.377E-04 | 2.733E-03 | CYP2C9, CYP1A2, AOX1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04915 | Estrogen signaling pathway | 6.864E-04 | 7.016E-03 | ESR1, EGFR, ESR2 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 1.110E-03 | 9.807E-03 | CYP2C9, ALDH2, HSD17B1, CYP1A2, CYP1A1, AKR1B1, AOX1, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.173E-03 | 9.807E-03 | CYP2C9, CYP1A2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F2; |
A00-B99: Certain infectious and parasitic diseases | Bacterial infections | A00-B99 | CYP2C9; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | ALDH2; |
C00-D49: Neoplasms | Advanced solid tumor | C00-C75, C7A, C7B | AURKA; |
K00-K95: Diseases of the digestive system | Gastrointestinal disease | K00-K93 | ESRRA; EGFR; |
N00-N99: Diseases of the genitourinary system | Irregularities | N92.6 | ESR1; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | KDR; EGFR; |
I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | ESR1; F2; |
G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | ACHE; |
C00-D49: Neoplasms | Renal cancer | C64 | KDR; CA9; |
C00-D49: Neoplasms | Renal cell carcinoma | NA | KDR; |
C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
A00-B99: Certain infectious and parasitic diseases | Cryptosporidium infection | A07.2 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | ACHE; |
J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | ESRRA; |
C00-D49: Neoplasms | AML | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | ESR1; |
Q00-Q99: Congenital malformations, deformations and chromosomal abnormalities | Osteopetrosis | Q78.2 | ESR1; |
Z00-Z99: Factors influencing health status and contact with health services | Oral contraceptive | Z30 | ESR1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatological disease | L00-L99 | ESRRA; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Dermatitis | L20-L30 | ESRRA; |
C00-D49: Neoplasms | Gastrointestinal cancers | C15-C26 | KDR; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; ACHE; |
Z00-Z99: Factors influencing health status and contact with health services | Hormone replacement therapy | Z79.890 | ESR1; |
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
L00-L99: Diseases of the skin and subcutaneous tissue | Diabetic foot ulcer | L88-L89 | EGFR; |
I00-I99: Diseases of the circulatory system | Angiogenesis disorder | I00-I99 | KDR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | ACHE; |
N00-N99: Diseases of the genitourinary system | Atrophic vaginitis | N95.2 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Estrogen deficiency | E28.39 | ESR1; |
C00-D49: Neoplasms | Hormone refractory prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | KDR; EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | ESR1; ACHE; |
G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | ACHE; |
A00-B99: Certain infectious and parasitic diseases | Pediculus humanus capitis | B85.0 | ACHE; |
C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | KDR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoporosis | M80-M81, Z79.890 | ESR1; |
C00-D49: Neoplasms | Ovarian cancer | C56 | KDR; EGFR; |
A00-B99: Certain infectious and parasitic diseases | Helminth infection | A00-B99 | ACHE; |
N00-N99: Diseases of the genitourinary system | Dyspareunia | N94.1 | ESR1; |
NA: NA | Early satiation associated with functional dyspepsia | NA | ACHE; |
I00-I99: Diseases of the circulatory system | Heart arrhythmia | I47-I49 | F2; |
C00-D49: Neoplasms | Colorectal cancer | C18-C21 | KDR; EGFR; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
C00-D49: Neoplasms | Esophageal cancer | C15 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Epileptic seizures | G40, P90, R56 | ACHE; |
C00-D49: Neoplasms | Cutaneous Melanoma | C43-C44 | KDR; |
N00-N99: Diseases of the genitourinary system | Infertility | N97.0 | ESR1; |
C00-D49: Neoplasms | Melanoma | C43 | KDR; EGFR; |
L00-L99: Diseases of the skin and subcutaneous tissue | Acne vulgaris | L70.0 | ESR1; ESRRA; |
Z00-Z99: Factors influencing health status and contact with health services | Contraception | Z30 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hypogonadism | E23.0, E28.3, E29.1 | ESR1; |
G00-G99: Diseases of the nervous system G00-G99 | Multiple scierosis | G35 | ESR1; F2; |
H00-H59: Diseases of the eye and adnexa | Choroidal neovascularisation | H35 | ESRRA; |
H00-H59: Diseases of the eye and adnexa | Chronic glaucoma | H40-H42 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poisoning due to pesticides and chemicals | T36-T50 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Female hypogonadism | E23, E28 | ESR1; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | ESR1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthralgia | M25.5 | ESR1; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | ESRRA; |
C00-D49: Neoplasms | Hematological malignancies | C81-C86 | AURKB; |
I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ALDH2; EGFR; |
N00-N99: Diseases of the genitourinary system | Female infertility due to anovulation | N97.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Female infertility | N97.0 | ESR1; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Thrombocytopenia | D69.6, P61.0 | F2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Atrophy | M62.571 | ESR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Atopic dermatitis | L00-L99 | F2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | ACHE; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Post-menopausal vaginal atrophy | N95.2 | ESR1; |
NA: NA | Postmenopausal disorder | NA | ESR1; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Substance dependence | F10-F19 | ALDH2; |
I00-I99: Diseases of the circulatory system | Stroke in atrial fibrillation | I48, I61-I63 | F2; |
C00-D49: Neoplasms | Chronic lymphocytic leukaemia | C91 | EGFR; |
C00-D49: Neoplasms | Fallopian tube cancer | C57.0, D28.2 | KDR; |
H00-H59: Diseases of the eye and adnexa | Eye disorders | H00-H59 | ESR1; |
C00-D49: Neoplasms | Peritoneal cavity cancer | NA | KDR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Poison intoxication | T36-T50 | ACHE; |
C00-D49: Neoplasms | Thyroid cancer | C73 | KDR; TSHR; |
I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F2; |
I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F2; |
C00-D49: Neoplasms | Locally advanced head and neck cancer | C07-C14, C32, C33 | EGFR; |
C00-D49: Neoplasms | Breast cancer | C50 | ESR1; KDR; EGFR; CYP19A1; CA9; |
C00-D49: Neoplasms | Brain cancer | C71, D33 | ESR1; EGFR; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood forming organ disorders | D75.9 | F2; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis | G70.0 | ACHE; |
C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | KDR; |
C00-D49: Neoplasms | Biliary cancer | C22, C24 | KDR; |
C00-D49: Neoplasms | Bladder cancer | C67 | EGFR; CYP19A1; |
I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F2; |
D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F2; |
I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F2; |
C00-D49: Neoplasms | Colon cancer | C50 | EGFR; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Vulnerary | S00-T98 | EGFR; |
I00-I99: Diseases of the circulatory system | Cardiovascular disorder | I00-I99 | KDR; F2; |
C00-D49: Neoplasms | Metastatic castration-resistant prostate cancer | C61 | KDR; |
C00-D49: Neoplasms | Metastatic breast cancer | C50 | KDR; |
N00-N99: Diseases of the genitourinary system | Menorrhagia | N92.0 | ESR1; |
N00-N99: Diseases of the genitourinary system | Menopause symptoms | N95.0 | ESR1; |
W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | ESRRA; AKR1B1; |
C00-D49: Neoplasms | Refractory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Cancer | C00-C96 | ESR1; AURKA; KDR; CSNK2A1; ACHE; EGFR; F2; CA9; |
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Cachexia | R64 | ESRRA; |
C00-D49: Neoplasms | Carcinoma | D00-D09 | ESR1; |
C00-D49: Neoplasms | Metastatic colorectal cancer | C18-C21 | KDR; EGFR; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mild cognitive impairment | F06.7 | ACHE; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | ESRRA; |
N00-N99: Diseases of the genitourinary system | Vagina disease | N76.0 | ESR1; |
I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F2; |
I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F2; |
C00-D49: Neoplasms | Advanced renal cell carcinoma | C64 | KDR; |
C00-D49: Neoplasms | Advanced cancers | C00-C96 | EGFR; |
C00-D49: Neoplasms | Advanced prostate cancer | C61 | ESR1; |
C00-D49: Neoplasms | Advanced malignancies | C00-C96 | KDR; |
NA: NA | Upper abdominal bloating | NA | ACHE; |
C00-D49: Neoplasms | Urethral cancer | NA | EGFR; |
N00-N99: Diseases of the genitourinary system | Urinary dysfunction | N39.3-N39.4 | ACHE; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | ESRRA; |
F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Female sexual dysfunction | F52 | ESR1; |
C00-D49: Neoplasms | Gastric cancer | C16 | KDR; EGFR; |
C00-D49: Neoplasms | Medullary thyroid cancer | C73 | KDR; |
C00-D49: Neoplasms | Malignant tumor | C00-C75, C7A, C7B | EGFR; |
NA: NA | Menopausal disorder | NA | ESR1; |
C00-D49: Neoplasms | Lymphoma | C81-C86 | EGFR; CA9; |
C00-D49: Neoplasms | Squamous cell cancer of head and neck | NA | KDR; |
C00-D49: Neoplasms | Solid tumours | C00-D48 | AURKA; AURKB; KDR; EGFR; F2; CA9; |
C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR; |
A00-B99: Certain infectious and parasitic diseases | Trematode infection | B66.9 | ESR1; |
C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | AURKA; AURKB; |
C00-D49: Neoplasms | Head and neck squamous cell carcinoma | C44 | EGFR; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | KDR; EGFR; AKR1B1; |
C00-D49: Neoplasms | Leukemia | C90-C95 | ESR1; |
C00-D49: Neoplasms | Late-stage solid tumors | C00-C75, C7A, C7B, D10-D36, D3A | AURKA; |
C00-D49: Neoplasms | Liver cancer | C22 | KDR; |
I00-I99: Diseases of the circulatory system | Myocardial infarction | I21, I22 | F2; |
L00-L99: Diseases of the skin and subcutaneous tissue | Psoriasis | L40 | EGFR; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Prostate cancer | C61 | ESR1; EGFR; |
C00-D49: Neoplasms | Adrenocortical carcinoma | C74.0 | ESR1; |
K00-K95: Diseases of the digestive system | Xerostomia | K11.7, R68.2 | ACHE; |
NA: NA | Nonvalvular atrial fibrillation | NA | F2; |
C00-D49: Neoplasms | Haematological malignancies | C81-C86 | AURKA; |
C00-D49: Neoplasms | Lung cancer | C33-C34 | EGFR; |
G00-G99: Diseases of the nervous system G00-G99 | Myasthenia gravis diagnosis | G70.0 | ACHE; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hormone deficiency | E00-E90 | ESR1; |
C00-D49: Neoplasms | Glioblastoma multiforme | C71 | EGFR; |
C00-D49: Neoplasms | Glioma | C71 | KDR; EGFR; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ACHE; AKR1B1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; |
NA: NA | Gonorrheal vaginitis | NA | ESR1; |
C00-D49: Neoplasms | Inflammatory breast cancer | C50 | EGFR; |
C00-D49: Neoplasms | Non-small-cell lung cancer | NA | KDR; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | ESRRA; |